{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:40:20Z","timestamp":1792176020033,"version":"4.4.0"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004366","name":"Tabriz University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004366","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021771","name":"Student Research Committee, Tabriz University of Medical Sciences","doi-asserted-by":"publisher","award":["72187"],"award-info":[{"award-number":["72187"]}],"id":[{"id":"10.13039\/501100021771","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.msard.2025.106845","type":"journal-article","created":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T03:57:41Z","timestamp":1762574261000},"page":"106845","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Antimuscarinics in multiple sclerosis: A systematic review"],"prefix":"10.1016","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-0584-8750","authenticated-orcid":false,"given":"Afra","family":"Darvishi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2540-6827","authenticated-orcid":false,"given":"Sina","family":"Pakkhesal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4752-0394","authenticated-orcid":false,"given":"Ali","family":"Alipour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8714-2470","authenticated-orcid":false,"given":"Zahra","family":"Jafari Shendi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9684-4088","authenticated-orcid":false,"given":"Reyhaneh","family":"HajEbrahimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1231-9043","authenticated-orcid":false,"given":"Negar","family":"Asiaban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5099-3369","authenticated-orcid":false,"given":"Nazli","family":"Asadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7613-3913","authenticated-orcid":false,"given":"Mahnaz","family":"Talebi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9030-2106","authenticated-orcid":false,"given":"Hanieh","family":"Salehi-Pourmehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9723-0109","authenticated-orcid":false,"given":"Amirreza","family":"Naseri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.msard.2025.106845_bib0001","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1111\/bph.15750","article-title":"A positive allosteric modulator for the muscarinic receptor (M1 mAChR) improves pathology and cognitive deficits in female APPswe\/PSEN1\u0394E9 mice","volume":"179","author":"Abd-Elrahman","year":"2022","journal-title":"Br. J. Pharmacol."},{"issue":"3\u20134","key":"10.1016\/j.msard.2025.106845_bib0002","doi-asserted-by":"crossref","first-page":"E110","DOI":"10.5489\/cuaj.4059","article-title":"Treatment of lower urinary tract symptoms in multiple sclerosis patients: review of the literature and current guidelines","volume":"11","author":"Aharony","year":"2017","journal-title":"Can. Urol. Assoc. J."},{"key":"10.1016\/j.msard.2025.106845_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104476","article-title":"The relationship between severity of overactive bladder symptoms and cognitive dysfunction, anxiety and depression in female patients with multiple sclerosis: running head: OAB-V8, BICAMS and HAD scale in MS","volume":"70","author":"Akko\u00e7","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"2","key":"10.1016\/j.msard.2025.106845_bib0004","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1179\/2045772315Y.0000000021","article-title":"Overactive bladder symptoms in patients with multiple sclerosis: frequency, severity, diagnosis and treatment [Article]","volume":"39","author":"Akko\u00e7","year":"2016","journal-title":"J. Spinal Cord Med."},{"issue":"2","key":"10.1016\/j.msard.2025.106845_bib0005","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/nau.22945","article-title":"Solifenacin is effective and well tolerated in patients with neurogenic detrusor overactivity: results from the double-blind, randomized, active- and placebo-controlled SONIC urodynamic study","volume":"36","author":"Amarenco","year":"2017","journal-title":"Neurourol. Urodyn."},{"issue":"5","key":"10.1016\/j.msard.2025.106845_bib0006","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.eururo.2008.01.007","article-title":"Effective treatment of neurogenic detrusor dysfunction by combined high-dosed antimuscarinics without increased side-effects","volume":"53","author":"Amend","year":"2008","journal-title":"Eur. Urol."},{"key":"10.1016\/j.msard.2025.106845_bib0007","doi-asserted-by":"crossref","DOI":"10.1177\/17562872221122484","article-title":"Antimuscarinics for neurogenic overactive bladder in multiple sclerosis: real-life data","volume":"14","author":"Andretta","year":"2022","journal-title":"Ther. Adv. Urol."},{"key":"10.1016\/j.msard.2025.106845_bib0008","series-title":"JBI Manual For Evidence Synthesis","author":"Aromataris","year":"2020"},{"issue":"4","key":"10.1016\/j.msard.2025.106845_bib0009","doi-asserted-by":"crossref","first-page":"492","DOI":"10.4081\/aiua.2022.4.492","article-title":"Efficacy of overactive neurogenic bladder treatment: a systematic review of randomized controlled trials","volume":"94","author":"Bapir","year":"2022","journal-title":"Arch. Ital. Urol. Androl."},{"issue":"3","key":"10.1016\/j.msard.2025.106845_bib0010","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1023\/A:1017553200693","article-title":"Clinical management of the neurourological syndrome associated with multiple sclerosis and correlations to grade of the disease [Article]","volume":"32","author":"Barbalias","year":"2001","journal-title":"Int. Urol. Nephrol."},{"issue":"3","key":"10.1016\/j.msard.2025.106845_bib0011","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1023\/A:1017597016622","article-title":"Vesicourethral dysfunction associated with multiple sclerosis: correlations among response, most prevailing clinical status and grade of the disease","volume":"32","author":"Barbalias","year":"2001","journal-title":"Int. Urol. Nephrol."},{"issue":"3","key":"10.1016\/j.msard.2025.106845_bib0012","doi-asserted-by":"crossref","first-page":"378","DOI":"10.11124\/JBIES-23-00268","article-title":"The revised JBI critical appraisal tool for the assessment of risk of bias for quasi-experimental studies","volume":"22","author":"Barker","year":"2024","journal-title":"JBI. Evid. Synth."},{"issue":"2","key":"10.1016\/j.msard.2025.106845_bib0014","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1097\/01.ju.0000103274.38694.b1","article-title":"Can higher doses of oxybutynin improve efficacy in neurogenic bladder?","volume":"171","author":"Bennett","year":"2004","journal-title":"J. Urol."},{"issue":"5","key":"10.1016\/j.msard.2025.106845_bib0015","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1191\/1352458503ms957oa","article-title":"Symptomatic medication use in multiple sclerosis [Article]","volume":"9","author":"Brichetto","year":"2003","journal-title":"Multiple Sclerosis"},{"key":"10.1016\/j.msard.2025.106845_bib0016","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.urology.2020.08.008","article-title":"Mirabegron versus Solifenacin in multiple sclerosis patients with overactive bladder symptoms: a prospective comparative nonrandomized study","volume":"145","author":"Brucker","year":"2020","journal-title":"Urology."},{"issue":"4","key":"10.1016\/j.msard.2025.106845_bib0017","first-page":"311","article-title":"Prevalence and factors associated with cumulative anticholinergic burden among older long-stay nursing home residents with overactive bladder [Article]","volume":"38","author":"Chatterjee","year":"2021","journal-title":"Drugs and Aging"},{"issue":"4","key":"10.1016\/j.msard.2025.106845_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.molpha.2025.100027","article-title":"Enhancing remyelination in multiple sclerosis via M1 muscarinic acetylcholine receptor","volume":"107","author":"Chen","year":"2025","journal-title":"Mol. Pharmacol."},{"issue":"4","key":"10.1016\/j.msard.2025.106845_bib0019","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.msard.2012.05.002","article-title":"Cognitive impact of anticholinergic medication in MS: adding insult to injury?","volume":"1","author":"Cruce","year":"2012","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"5","key":"10.1016\/j.msard.2025.106845_bib0020","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/dneu.20976","article-title":"Muscarinic receptor subtypes as potential targets to modulate oligodendrocyte progenitor survival, proliferation, and differentiation","volume":"72","author":"De Angelis","year":"2012","journal-title":"Dev. Neurobiol."},{"issue":"7471","key":"10.1016\/j.msard.2025.106845_bib0021","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nature12647","article-title":"A regenerative approach to the treatment of multiple sclerosis","volume":"502","author":"Deshmukh","year":"2013","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.msard.2025.106845_bib0022","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.purol.2015.12.005","article-title":"Anticholinergics do not affect the sexual function in women diagnosed with multiple sclerosis","volume":"26","author":"Di Marco","year":"2016","journal-title":"Progres En Urol."},{"issue":"1","key":"10.1016\/j.msard.2025.106845_bib0023","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/ene.13819","article-title":"Multiple sclerosis - a review","volume":"26","author":"Dobson","year":"2019","journal-title":"Eur. J. Neurol."},{"issue":"7","key":"10.1016\/j.msard.2025.106845_bib0024","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1046\/j.1464-410x.2001.02134.x","article-title":"Systemic effects of intravesical atropine sulphate","volume":"87","author":"Enskat","year":"2001","journal-title":"BJU Int."},{"issue":"3","key":"10.1016\/j.msard.2025.106845_bib0025","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1080\/10790268.2004.11753751","article-title":"Efficacy and safety of tolterodine in people with neurogenic detrusor overactivity","volume":"27","author":"Ethans","year":"2004","journal-title":"J. Spinal Cord. Med."},{"issue":"1","key":"10.1016\/j.msard.2025.106845_bib0026","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.juro.2006.08.099","article-title":"Intravesical atropine compared to oral oxybutynin for neurogenic detrusor overactivity: a double-blind, randomized crossover trial","volume":"177","author":"Fader","year":"2007","journal-title":"J. Urol."},{"issue":"3 Suppl","key":"10.1016\/j.msard.2025.106845_bib0027","first-page":"S9","article-title":"The overactive bladder in multiple sclerosis","volume":"100","author":"Fingerman","year":"2000","journal-title":"J. Am. Osteopath. Assoc."},{"issue":"4","key":"10.1016\/j.msard.2025.106845_bib0028","doi-asserted-by":"crossref","first-page":"380","DOI":"10.7861\/clinmed.2020-0292","article-title":"Clinical presentation and diagnosis of multiple sclerosis","volume":"20","author":"Ford","year":"2020","journal-title":"Clin. Med. (Lond)"},{"issue":"5","key":"10.1016\/j.msard.2025.106845_bib0029","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/S0022-5347(17)45940-4","article-title":"Oxybutynin versus propantheline in patients with multiple sclerosis and detrusor hyperreflexia","volume":"135","author":"Gajewski","year":"1986","journal-title":"J. Urol."},{"issue":"9","key":"10.1016\/j.msard.2025.106845_bib0030","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s12325-013-0054-z","article-title":"OnabotulinumtoxinA is effective in patients with urinary incontinence due to neurogenic detrusor overactivity [corrected] regardless of concomitant anticholinergic use or neurologic etiology","volume":"30","author":"Ginsberg","year":"2013","journal-title":"Adv. Ther."},{"issue":"8","key":"10.1016\/j.msard.2025.106845_bib0031","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1007\/s00345-020-03555-8","article-title":"B3 agonists or anticholinergics in the treatment of the lower urinary tract dysfunction in patients with multiple sclerosis?-A randomized study","volume":"39","author":"Glykas","year":"2021","journal-title":"World J. Urol."},{"issue":"1","key":"10.1016\/j.msard.2025.106845_bib0032","first-page":"65","article-title":"Comparative effectiveness of anticholinergic agents for lower urinary tract symptoms","volume":"24","author":"Goodson","year":"2018","journal-title":"J. Manage Care Spec. Pharm."},{"issue":"10111","key":"10.1016\/j.msard.2025.106845_bib0033","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1016\/S0140-6736(17)32346-2","article-title":"Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial","volume":"390","author":"Green","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.msard.2025.106845_bib0034","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/s00345-025-05655-9","article-title":"Clinical and urodynamic benefit of adding antimuscarinics after a loss of efficacy of intradetrusor botulinum toxin in patients with multiple sclerosis","volume":"43","author":"Haegel","year":"2025","journal-title":"World J. Urol."},{"issue":"1","key":"10.1016\/j.msard.2025.106845_bib0035","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/nau.25614","article-title":"Safety and efficacy of trospium chloride and solifenacin in stroke-induced neurogenic lower urinary tract dysfunction: a randomized controlled trial","volume":"44","author":"Hajebrahimi","year":"2025","journal-title":"Neurourol. Urodyn."},{"issue":"5","key":"10.1016\/j.msard.2025.106845_bib0036","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/nau.20289","article-title":"Neurogenic bladder treatment by doubling the recommended antimuscarinic dosage","volume":"25","author":"Horstmann","year":"2006","journal-title":"Neurourol. Urodyn."},{"key":"10.1016\/j.msard.2025.106845_bib0037","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.111481","article-title":"The preferential effect of Clemastine on F3\/Contactin-1\/Notch-1 compared to Jagged-1\/Notch-1 justifies its remyelinating effect in an experimental model of multiple sclerosis in rats","volume":"128","author":"Ibrahim","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.msard.2025.106845_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103559","article-title":"Pelvic floor muscle training in multiple sclerosis patients with lower urinary tract dysfunction: a systematic review and meta-analysis","volume":"59","author":"Kajbafvala","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.msard.2025.106845_bib0039","doi-asserted-by":"crossref","first-page":"4091","DOI":"10.1038\/s41598-024-53615-x","article-title":"Clemastine and metformin extend the window of NMDA receptor surface expression in ageing oligodendrocyte precursor cells","volume":"14","author":"Kamen","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.msard.2025.106845_bib0040","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jaut.2014.01.022","article-title":"The diagnosis of multiple sclerosis and the various related demyelinating syndromes: a critical review","volume":"48-49","author":"Karussis","year":"2014","journal-title":"J. Autoimmun."},{"issue":"11","key":"10.1016\/j.msard.2025.106845_bib0041","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1111\/j.1742-1241.2008.01849.x","article-title":"Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin","volume":"62","author":"Kay","year":"2008","journal-title":"Int. J. Clin. Pract."},{"issue":"8","key":"10.1016\/j.msard.2025.106845_bib0042","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1002\/nau.24790","article-title":"Efficacy of fesoterodine fumarate (8 mg) in neurogenic detrusor overactivity due to spinal cord lesion or multiple sclerosis: a prospective study","volume":"40","author":"Konstantinidis","year":"2021","journal-title":"Neurourol. Urodyn."},{"issue":"6","key":"10.1016\/j.msard.2025.106845_bib0043","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1590\/s1677-5538.ibju.2021.99.12","article-title":"Current pharmacotherapy of overactive bladder","volume":"47","author":"Kreydin","year":"2021","journal-title":"Int. Braz. J. Urol."},{"issue":"7","key":"10.1016\/j.msard.2025.106845_bib0044","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10571-021-01089-0","article-title":"The notch signaling pathway regulates differentiation of NG2 cells into oligodendrocytes in demyelinating diseases","volume":"42","author":"Li","year":"2022","journal-title":"Cell. Mol. Neurobiol."},{"issue":"6","key":"10.1016\/j.msard.2025.106845_bib0045","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/j.1464-410X.2008.08093.x","article-title":"Propiverine vs oxybutynin for treating neurogenic detrusor overactivity in children and adolescents: results of a multicentre observational cohort study [Article]","volume":"103","author":"Madersbacher","year":"2009","journal-title":"BJU Int."},{"key":"10.1016\/j.msard.2025.106845_bib0046","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2023.1107886","article-title":"Solifenacin versus posterior tibial nerve stimulation for overactive bladder in patients with multiple sclerosis","volume":"17","author":"Majdinasab","year":"2023","journal-title":"Front. Neurosci."},{"issue":"2","key":"10.1016\/j.msard.2025.106845_bib0047","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.juro.2016.10.112","article-title":"Nocturnal urinary disorders and Multiple sclerosis: clinical and urodynamic study of 309 patients","volume":"197","author":"Mauruc","year":"2017","journal-title":"J. Urol."},{"issue":"8","key":"10.1016\/j.msard.2025.106845_bib0048","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/nm.3618","article-title":"Micropillar arrays as a high-throughput screening platform for therapeutics in multiple sclerosis","volume":"20","author":"Mei","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.msard.2025.106845_bib0049","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.18246","article-title":"Accelerated remyelination during inflammatory demyelination prevents axonal loss and improves functional recovery","volume":"5","author":"Mei","year":"2016","journal-title":"Elife"},{"issue":"6","key":"10.1016\/j.msard.2025.106845_bib0050","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1021\/acsptsci.9b00068","article-title":"Remyelination pharmacotherapy investigations highlight diverse mechanisms underlying multiple sclerosis progression","volume":"2","author":"Melchor","year":"2019","journal-title":"ACS. Pharmacol. Transl. Sci."},{"issue":"6","key":"10.1016\/j.msard.2025.106845_bib0051","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/j.1464-410X.1980.tb03093.x","article-title":"The urodynamic and subjective results of treatment of detrusor instability with oxybutynin chloride [Article]","volume":"52","author":"Moisey","year":"1980","journal-title":"Br. J. Urol."},{"issue":"10","key":"10.1016\/j.msard.2025.106845_bib0052","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/S1474-4422(25)00270-4","article-title":"Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria","volume":"24","author":"Montalban","year":"2025","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2025.106845_bib0053","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jns.2017.11.028","article-title":"Anti-cholinergic medications for bladder dysfunction worsen cognition in persons with multiple sclerosis","volume":"385","author":"Morrow","year":"2018","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2025.106845_bib0054","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.105337","article-title":"Effectiveness of tibial nerve stimulation in neurogenic lower urinary tract dysfunction among patients with Multiple sclerosis: a systematic review and meta-analysis","volume":"80","author":"Mosaddeghi-Heris","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"Supp. 1","key":"10.1016\/j.msard.2025.106845_bib0055","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.5152\/tud.2020.20092","article-title":"Lower urinary tract dysfunction in common neurological diseases","volume":"46","author":"Moussa","year":"2020","journal-title":"Turk. J. Urol."},{"issue":"3","key":"10.1016\/j.msard.2025.106845_bib0056","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/XEB.0000000000000054","article-title":"Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data","volume":"13","author":"Munn","year":"2015","journal-title":"Int. J. Evid. Based. Healthc."},{"issue":"4","key":"10.1016\/j.msard.2025.106845_bib0057","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/WNF.0000000000000596","article-title":"Efficacy and safety of Mirabegron add-on therapy after failure with Solifenacin in multiple sclerosis patients with overactive bladder: a pilot study","volume":"47","author":"Mut","year":"2024","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.msard.2025.106845_bib0058","doi-asserted-by":"crossref","DOI":"10.1590\/1980-5764-dn-2022-0053","article-title":"Cognitive effects of individual anticholinergic drugs: a systematic review and meta-analysis","volume":"17","author":"Naseri","year":"2023","journal-title":"Dement. Neuropsychol."},{"key":"10.1016\/j.msard.2025.106845_bib78","first-page":"455","article-title":"The effects of oxybutynin on cognitive function; a systematic review","author":"Naseri","year":"2023","journal-title":"Journal of the Neurological Sciences"},{"key":"10.1016\/j.msard.2025.106845_bib0059","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.105339","article-title":"The management of lower urinary tract symptoms in multiple sclerosis: an umbrella review","volume":"80","author":"Naseri","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"5","key":"10.1016\/j.msard.2025.106845_bib0060","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1111\/j.1464-410X.1993.tb16210.x","article-title":"Intravesical instillation of oxybutynin hydrochloride for detrusor hyper-reflexia [Article]","volume":"72","author":"O'Flynn","year":"1993","journal-title":"Br. J. Urol."},{"issue":"3","key":"10.1016\/j.msard.2025.106845_bib0061","doi-asserted-by":"crossref","first-page":"116","DOI":"10.7224\/1537-2073-4.3.116","article-title":"Changes in voiding patterns in patients with MS and extended-release oxybutynin","volume":"4","author":"O'Leary","year":"2002","journal-title":"Int. J. MS. Care"},{"issue":"1","key":"10.1016\/j.msard.2025.106845_bib0062","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014A web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst. Rev."},{"key":"10.1016\/j.msard.2025.106845_bib0063","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.msard.2025.106845_bib0064","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrurol.2016.53","article-title":"Management of neurogenic bladder in patients with multiple sclerosis [Review]","volume":"13","author":"Ph\u00e9","year":"2016","journal-title":"Nat. Rev. Urol."},{"issue":"32","key":"10.1016\/j.msard.2025.106845_bib0065","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2407974121","article-title":"Targeting the muscarinic M1 receptor with a selective, brain-penetrant antagonist to promote remyelination in multiple sclerosis","volume":"121","author":"Poon","year":"2024","journal-title":"Proc. Natl. Acad. Sci. u S. a"},{"issue":"1","key":"10.1016\/j.msard.2025.106845_bib0066","first-page":"33","article-title":"Detrusor hyperreflexia in multiple sclerosis. Alleviation by a combination of imipramine and propantheline, a clinico-laboratory study [Article]","volume":"18","author":"Rabey","year":"1979","journal-title":"Eur. Neurol."},{"key":"10.1016\/j.msard.2025.106845_bib0067","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainresbull.2025.111278","article-title":"FMRI insights into the neural alterations and clinical correlates in multiple sclerosis: a comprehensive overview of systematic reviews and meta-analyses","volume":"223","author":"Rahnemayan","year":"2025","journal-title":"Brain Res. Bull."},{"issue":"10","key":"10.1016\/j.msard.2025.106845_bib0068","article-title":"Pelvic floor muscle training and its benefits for multiple sclerosis patients suffering from urinary incontinence and sexual dysfunction","volume":"15","author":"Sapouna","year":"2023","journal-title":"Cureus."},{"issue":"1","key":"10.1016\/j.msard.2025.106845_bib0069","doi-asserted-by":"crossref","first-page":"6160","DOI":"10.1038\/s41598-022-10095-1","article-title":"Oscillatory calcium release and sustained store-operated oscillatory calcium signaling prevents differentiation of human oligodendrocyte progenitor cells","volume":"12","author":"Seidman","year":"2022","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.msard.2025.106845_bib0070","doi-asserted-by":"crossref","first-page":"100","DOI":"10.5152\/tud.2023.22241","article-title":"Efficacy of tibial nerve stimulation in neurogenic lower urinary tract dysfunction among patients with Multiple sclerosis: a systematic review and meta-analysis","volume":"49","author":"Tahmasbi","year":"2023","journal-title":"Urol Res Pract"},{"key":"10.1016\/j.msard.2025.106845_bib0071","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.914153","article-title":"Clemastine promotes differentiation of oligodendrocyte progenitor cells through the activation of ERK1\/2 via muscarinic receptors after spinal cord injury","volume":"13","author":"Tong","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"12","key":"10.1016\/j.msard.2025.106845_bib0072","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1007\/s00415-016-8212-2","article-title":"Neurogenic lower urinary tract dysfunction: evaluation and management [Article]","volume":"263","author":"Tudor","year":"2016","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2025.106845_bib0073","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/834753","article-title":"Solifenacin in multiple sclerosis patients with overactive bladder: a prospective study","volume":"2011","author":"van Rey","year":"2011","journal-title":"Adv. Urol."},{"issue":"4","key":"10.1016\/j.msard.2025.106845_bib0074","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.purol.2016.10.005","article-title":"Prospective evaluation of mouth and eye dryness induced by antimuscarinic drugs used for neurogenic overactive bladder in 35 patients with multiple sclerosis","volume":"27","author":"Weglinski","year":"2017","journal-title":"Progres En Urologie"},{"issue":"7","key":"10.1016\/j.msard.2025.106845_bib0075","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/sj.mp.4002064","article-title":"Quetiapine facilitates oligodendrocyte development and prevents mice from myelin breakdown and behavioral changes","volume":"13","author":"Xiao","year":"2008","journal-title":"Mol. Psychiatry"},{"issue":"10","key":"10.1016\/j.msard.2025.106845_bib0076","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/cns.12154","article-title":"Quetiapine fumarate for the treatment of multiple sclerosis: focus on myelin repair","volume":"19","author":"Zhornitsky","year":"2013","journal-title":"CNS. Neurosci. Ther."},{"issue":"3","key":"10.1016\/j.msard.2025.106845_bib0077","doi-asserted-by":"crossref","first-page":"271","DOI":"10.5644\/ama2006-124.267","article-title":"Effects of treating an overactive urinary bladder in patients with multiple sclerosis","volume":"48","author":"Zoni\u0107-Imamovi\u0107","year":"2019","journal-title":"Acta Med. Acad."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825005875?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825005875?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T03:24:02Z","timestamp":1784345042000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825005875"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":77,"alternative-id":["S2211034825005875"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106845","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antimuscarinics in multiple sclerosis: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106845","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106845"}}